Overview

Study of Cimzia for the Treatment of Ulcerative Colitis

Status:
Active, not recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if Cimzia (certolizumab pegol) is an effective treatment for patients with Ulcerative colitis.
Phase:
Phase 2
Details
Lead Sponsor:
Scott Lee
University of Washington
Collaborators:
UCB Pharma
University of Pennsylvania
Treatments:
Certolizumab Pegol